Cargando…
The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock
The cell-autonomous circadian clock regulates IgE- and IL-33-mediated mast cell activation, both of which are key events in the development of allergic diseases. Accordingly, clock modifiers could be used to treat allergic diseases, as well as many other circadian-related diseases, such as sleep and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941044/ https://www.ncbi.nlm.nih.gov/pubmed/31847374 http://dx.doi.org/10.3390/ijms20246320 |
_version_ | 1783484471473864704 |
---|---|
author | Ishimaru, Kayoko Nakajima, Shotaro Yu, Guannan Nakamura, Yuki Nakao, Atsuhito |
author_facet | Ishimaru, Kayoko Nakajima, Shotaro Yu, Guannan Nakamura, Yuki Nakao, Atsuhito |
author_sort | Ishimaru, Kayoko |
collection | PubMed |
description | The cell-autonomous circadian clock regulates IgE- and IL-33-mediated mast cell activation, both of which are key events in the development of allergic diseases. Accordingly, clock modifiers could be used to treat allergic diseases, as well as many other circadian-related diseases, such as sleep and metabolic disorders. The nuclear receptors REV-ERB-α and -β (REV-ERBs) are crucial components of the circadian clockwork. Efforts to pharmacologically target REV-ERBs using putatively specific synthetic agonists, particularly SR9009, have yielded beneficial effects on sleep and metabolism. Here, we sought to determine whether REV-ERBs are functional in the circadian clockwork in mast cells and, if so, whether SR9009 affects IgE- and IL-33-mediated mast cell activation. Bone marrow-derived mast cells (BMMCs) obtained from wild-type mice expressed REV-ERBs, and SR9009 or other synthetic REV-ERBs agonists affected the mast cell clockwork. SR9009 inhibited IgE- and IL-33-mediated mast cell activation in wild-type BMMCs in association with inhibition of Gab2/PI3K and NF-κB activation. Unexpectedly, these suppressive effects of SR9009 were observed in BMMCs following mutation of the core circadian gene Clock. These findings suggest that SR9009 inhibits IgE- and IL-33-mediated mast cell activation independently of the functional circadian clock activity. Thus, SR9009 or other synthetic REV-ERB agonists may have potential for anti-allergic agents. |
format | Online Article Text |
id | pubmed-6941044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69410442020-01-09 The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock Ishimaru, Kayoko Nakajima, Shotaro Yu, Guannan Nakamura, Yuki Nakao, Atsuhito Int J Mol Sci Article The cell-autonomous circadian clock regulates IgE- and IL-33-mediated mast cell activation, both of which are key events in the development of allergic diseases. Accordingly, clock modifiers could be used to treat allergic diseases, as well as many other circadian-related diseases, such as sleep and metabolic disorders. The nuclear receptors REV-ERB-α and -β (REV-ERBs) are crucial components of the circadian clockwork. Efforts to pharmacologically target REV-ERBs using putatively specific synthetic agonists, particularly SR9009, have yielded beneficial effects on sleep and metabolism. Here, we sought to determine whether REV-ERBs are functional in the circadian clockwork in mast cells and, if so, whether SR9009 affects IgE- and IL-33-mediated mast cell activation. Bone marrow-derived mast cells (BMMCs) obtained from wild-type mice expressed REV-ERBs, and SR9009 or other synthetic REV-ERBs agonists affected the mast cell clockwork. SR9009 inhibited IgE- and IL-33-mediated mast cell activation in wild-type BMMCs in association with inhibition of Gab2/PI3K and NF-κB activation. Unexpectedly, these suppressive effects of SR9009 were observed in BMMCs following mutation of the core circadian gene Clock. These findings suggest that SR9009 inhibits IgE- and IL-33-mediated mast cell activation independently of the functional circadian clock activity. Thus, SR9009 or other synthetic REV-ERB agonists may have potential for anti-allergic agents. MDPI 2019-12-14 /pmc/articles/PMC6941044/ /pubmed/31847374 http://dx.doi.org/10.3390/ijms20246320 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ishimaru, Kayoko Nakajima, Shotaro Yu, Guannan Nakamura, Yuki Nakao, Atsuhito The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock |
title | The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock |
title_full | The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock |
title_fullStr | The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock |
title_full_unstemmed | The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock |
title_short | The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock |
title_sort | putatively specific synthetic rev-erb agonist sr9009 inhibits ige- and il-33-mediated mast cell activation independently of the circadian clock |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941044/ https://www.ncbi.nlm.nih.gov/pubmed/31847374 http://dx.doi.org/10.3390/ijms20246320 |
work_keys_str_mv | AT ishimarukayoko theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT nakajimashotaro theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT yuguannan theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT nakamurayuki theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT nakaoatsuhito theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT ishimarukayoko putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT nakajimashotaro putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT yuguannan putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT nakamurayuki putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock AT nakaoatsuhito putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock |